Dyspepsia

Current Opinion in Gastroenterology

Volumn 24, Issue 6, 2008, Pages 692-697

  Quigley, Eamonn M M ^a,b   Keohane, John ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

Acid suppression; Dyspepsia; Functional dyspepsia; Gastric motility; Gastroesophageal reflux disease; Helicobacter pylori; Irritable bowel syndrome

Indexed keywords

ANTIDEPRESSANT AGENT; HERBACEOUS AGENT; IBEROGAST; ITOPRIDE; MIRTAZAPINE; NORTRIPTYLINE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; STW 5; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DOSE RESPONSE; DYSPEPSIA; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; IRRITABLE COLON; LOW DRUG DOSE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SENSORY SYSTEM; TREATMENT PLANNING;

ANTI-INFLAMMATORY AGENTS; DYSPEPSIA; GASTROINTESTINAL MOTILITY; HUMANS; INCIDENCE; INTESTINES; PROTON PUMP INHIBITORS; WORLD HEALTH;

EID: 55749101595     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328313b983     Document Type: Review

References (52)

1. Halder SL, Locke GR 3rd, Schleck CD, et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007; 133:799-807. This study describes in detail the natural history of functional gastrointestinal disorders (FGIDs) and of IBS and functional dyspepsia, in particular, and demonstrates that, although the point prevalence of both IBS and functional dyspepsia remained stable over the 12-year study period, there was substantial movement from one diagnosis to the other over time.
2. Minocha A, Wigington WC, Johnson WD. Detailed characterization of epidemiology of uninvestigated dyspepsia and its impact on quality of life among African-Americans as compared to Caucasians. Am J Gastroenterol 2006; 101:336-342.
3. Geeraerts B, Vandenberghe J, Van Oudenhove L, et al. Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology 2005; 129:1437-1444.
4. Halder SL, Locke GR, Schleck CD, et al. Influence of alcohol consumption on IBS and dyspepsia. Neurogastroenterol Motil 2006; 18:1001-1008.
5. Wildner-Christensen M, Hansen JM, De Muckadell OB. Risk factors for dyspepsia in a general population: nonsteroidal anti-inflammatory drugs, cigarette smoking and unemployment are more important than Helicobacter pylori infection. Scand J Gastroenterol 2006;41:149-154.
6. Cremonini F, Locke GR, Schleck CD, et al. Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohort. Neurogastroenterol Motil 2006;18:987-994.
7. Ford AC, Forman D, Bailey AG, et al. Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol 2007; 102:957-965. This study identifies factors which lead an individual with dyspepsia to seek medical care.
8. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl 2):II37-II42.
9. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466-1479.
10. Veldhuyzen van Zanten SJO, Flook N, Chiba N, et al., and for the Canadian Dyspepsia Working Group. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. CMAJ 2000; 162:3-23.
11. Moayyedi P, Talley NJ, Fennerty MB, Vakil N. Can the clinical history distinguish between organic and functional dyspepsia? JAMA 2006; 295:1566-1576.
12. Choung RS, Locke GR, Schleck CD, et al. Do distinct dyspepsia subgroups exist in the community? A population-based study. Am J Gastroenterol 2007; 102:1983-1989.
13. Haag S, Senf W, Häuser W, et al. Impairment of health-related quality of life in functional dyspepsia and chronic liver disease: the influence of depression and anxiety. Aliment Pharmaool Ther 2008; 27:561-571.
14. Keohane J, Quigley EMM. Functional dyspepsia and non-erosive reflux disease: clinical Interactions and their implications. Med Gen Med 2007; 9:31-36.
15. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101:1900-1920.
16. El-Serag HB, Talley NJ. Systematic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004; 19:643-654.
17. Conchillo JM, Selimah M, Bredenoord AJ, et al. Air swallowing, belching, acid and nonacid reflux in patients with functional dyspepsia. Aliment Pharmacol Ther 2007; 25:965-971.
18. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127:1239-1255.
19. van den Elzen BD, van den Wijngaard RM, Tytgat GN, Boeckxstaens GE. Influence of corticotropin-releasing hormone on gastric sensitivity and motor function In healthy volunteers. Eur J Gastroenterol Hepatol 2007; 19:401-407.
20. Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007; 22:304-310. This study nicely summarizes the frustrations of prokinetic studies in functional dyspepsia; overall there is no benefit for prokinetics; some individual drugs show some modest benefits.
21. Takamori K, Mizuta Y, Takeshima F, et al. Relation among plasma ghrelin level, gastric emptying, and psychologic condition in patients with functional dyspepsia. J Clin Gastroenterol 2007; 41:477-483.
22. Akamizu T, Iwakura H, Ariyasu H, et al., FD Clinical Study Team. Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite. Eur J Endocrinol 2008; 158:491-498.
23. Lawal A, Barboi A, Krasnow A, et al. Rapid gastric emptying is more common than gastroparesis in patients with autonomic dysfunction. Am J Gastroenterol 2007; 102:618-623.
24. van den Elzen BD, Bennink RJ, Holman R, et al. Impaired drinking capacity in patients with functional dyspepsia: intragastric distribution and distal stomach volume. Neurogastroenterol Motil 2007; 19:968-976.
25. Choung RS, Cremonini F, Thapa P, et al. The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial. Neurogastroenterol Motil 2008; 20:220-227.
26. Vandenberghe J, Dupont P, Van Oudenhove L, et al. Regional cerebral blood flow during gastric balloon distension in functional dyspepsia. Gastroenterology 2007; 132:1684-1693. This study extends observations made with advanced imaging techniques in IBS to functional dyspepsia.
27. Lembo A, Zaman M, Jones M, Talley NJ. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther 2007; 25:1343-1350.
28. Arisawa T, Tahara T, Shibata T, et al. Genetic polymorphisms of molecules associated with inflammation and immune response in Japanese subjects with functional dyspepsia, Int J Mol Med 2007; 20:717-723.
29. Gargala G, Lecleire S, Francois A, et al. Duodenal intraepithelial T lymphocytes in patients with functional dyspepsia. World J Gastroenterol 2007; 13:2333-2338.
30. Talley NJ, Walker MM, Aro P, et al. Nonulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007; 5:1175-1183. From data generated in a population study in Sweden, the authors report a significant association between duodenal mucosal eosinophilia and dyspepsia.
31. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for nonulcer dyspepsia. Cochrane Database Syst Rev 2006:CD001960.
32. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for nonulcer dyspepsia. Cochrane Database Syst Rev 2006:CD002096.
33. Ford AC, Qume M, Moayyedi P, et al. Helicobacter pylori 'test and treat' or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005; 128:1838-1844.
34. Barton PM, Moayyedi P, Talley NJ, et al. A second-order simulation model of the cost-effectiveness of managing dyspepsia in the United States. Med Decis Making 2008; 28:44-55.
35. van Kerkhoven LA, van Rossum LG, van Oijen MG, et al. Upper gastrointestinal endoscopy does not reassure patients with functional dyspepsia. Endoscopy 2006; 38:879-885.
36. Ford AC, Forman D, Nathan J, et al. Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. Aliment Pharmacol Ther 2007; 26:1267-1275.
37. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006; 131:390-401.
38. Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007; 5:178-185.
39. Gwee KA, Hwang JE, Ho KY, et al. In-practice predictors of response to proton pump inhibitor therapy in primary care patients with dyspepsia in an Asian population. J Clin Gastroenterol 2008; 42:134-138.
40. Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008; 336:651-654.
41. Talley NJ, Vakil N, Lauritsen K, et al., STARS I Study Group. Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response? Aliment Pharmacol Ther 2007; 26:673-682.
42. van Zanten SV, Rook N, Talley NJ, et al., STARS II Study Group. One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study. Aliment Pharmacol Ther 2007; 26:665-672.
43. Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354:832-840.
44. Boeckxstaens GE, Tytgat GN, Wajs E, et al. The influence of the novel 5-HT1A agonist R137696 on the proximal stomach function in healthy volunteers. Neurogastroenterol Motil 2006; 18:919-926.
45. Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter 2007; 12:541-546.
46. Talley NJ. How to manage the difficult-to-treat dyspeptic patient. Nat Clin Pract Gastroenterol Hepatol 2007; 4:35-42.
47. Klupińska G, Poplawski T, Drzewoski J, et al. Therapeutic effect of melatonin in patients with functional dyspepsia. J Clin Gastroenterol 2007; 41:270-274.
48. Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005; 40:1036-1042.
49. Soo S, Moayyedi P, Deeks J, et al. Psychological interventions for nonulcer dyspepsia. Cochrane Database Syst Rev 2005:CD002301.
50. von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled doubleblind study. Am J Gastroenterol 2007; 102:1268-1275.
51. Melzer J, Rösch W, Reichling J, et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (lberogast). Aliment Pharmacol Ther 2004; 20:1279-1287.
52. Pilichiewicz AN, Horowitz M, Russo A, et al. Effects of lberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102:1276-1283.